Why the study?
Does pimobendan reduce treatment failure in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy?
Does pimobendan reduce treatment failure in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy?
Pimobendan significantly prolongs time to treatment failure when added to conventional therapy in Doberman Pinschers with CHF caused by DCM.
Answers are grounded in this paper and cite their sources.
Supports pimobendan evaluation in canine DCM; hypothesis-generating and should not yet change practice.
BACKGROUND: Despite traditional therapy of a diuretic, angiotensin converting enzyme inhibitor, digoxin, or a combination of these drugs, survival of dogs with dilated cardiomyopathy (DCM) is low. Pimobendan, an inodilator, has both inotropic and balanced peripheral vasodilatory properties. HYPOTHESIS: Pimobendan when added to conventional therapy will improve morbidity and reduce case fatality rate in Doberman Pinschers with congestive heart failure (CHF) caused by DCM. ANIMALS: Sixteen Doberman Pinschers in CHF caused by DCM. METHODS: A prospective randomized, double-blind, placebo-controlled study with treatment failure as the primary and quality of life (QoL) indices as secondary outcome variables. Therapy consisted of furosemide (per os [PO] as required) and benazepril hydrochloride (0.5 mg/kg PO q12h) and dogs were randomized in pairs and by sex to receive pimobendan (0.25 mg/kg PO q12h) or placebo (1 tablet PO q12h). RESULTS: Pimobendan-treated dogs had a significant improvement in time to treatment failure (pimobendan median, 130.5 days; placebo median, 14 days; P= .002; risk ratio = 0.35, P= .003, lower 5% confidence limit = 0.13, upper 95% confidence limit = 0.71). Number and rate of dogs reaching treatment failure in the placebo group precluded the analysis of QoL. CONCLUSIONS AND CLINICAL IMPORTANCE: Pimobendan should be used as a first-line therapeutic in Doberman Pinschers for the treatment of CHF caused by DCM.
No takes yet. Share an insight, caveat, or question.
O'Grady et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: